TUCSON, Ariz.--(BUSINESS WIRE)--Ventana Medical Systems, Inc. (NASDAQ: VMSI), the global leader in tissue-based cancer diagnostics, today announced that it has submitted its INFORM™ HER2 DNA Probe Assay to the Food and Drug Administration (FDA) for approval to market the product in the United States. The Test detects HER2 gene amplification through proprietary Silver in situ Hybridization (SISH) technology. Ventana’s HER2 SISH technology is currently used in Europe, Canada, Asia, and Australia.
